4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Bought by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. increased its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 23.3% in the 4th quarter, Holdings Channel reports. The firm owned 5,872 shares of the company’s stock after purchasing an additional 1,110 shares during the period. Daiwa Securities Group Inc.’s holdings in 4D Molecular Therapeutics were worth $119,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of FDMT. Vontobel Holding Ltd. purchased a new stake in 4D Molecular Therapeutics during the 4th quarter valued at about $2,887,000. Mirae Asset Global Investments Co. Ltd. grew its stake in 4D Molecular Therapeutics by 14.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,612 shares of the company’s stock valued at $438,000 after acquiring an additional 2,700 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in 4D Molecular Therapeutics during the 4th quarter valued at about $966,000. China Universal Asset Management Co. Ltd. grew its stake in 4D Molecular Therapeutics by 359.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,951 shares of the company’s stock valued at $100,000 after acquiring an additional 3,873 shares in the last quarter. Finally, SG Americas Securities LLC grew its stake in 4D Molecular Therapeutics by 119.5% during the 4th quarter. SG Americas Securities LLC now owns 26,899 shares of the company’s stock valued at $545,000 after acquiring an additional 14,645 shares in the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Stock Performance

4D Molecular Therapeutics stock opened at $23.25 on Friday. 4D Molecular Therapeutics, Inc. has a fifty-two week low of $9.44 and a fifty-two week high of $36.25. The firm has a 50 day moving average price of $28.60 and a 200 day moving average price of $20.71. The company has a market capitalization of $1.19 billion, a PE ratio of -8.74 and a beta of 2.87.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its earnings results on Thursday, February 29th. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.09). 4D Molecular Therapeutics had a negative net margin of 436.30% and a negative return on equity of 34.14%. The company had revenue of ($0.02) million during the quarter, compared to analyst estimates of $4.67 million. As a group, equities research analysts forecast that 4D Molecular Therapeutics, Inc. will post -3.03 earnings per share for the current year.

Insider Activity at 4D Molecular Therapeutics

In related news, insider Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $25.74, for a total value of $45,045.00. Following the completion of the sale, the insider now owns 1,737 shares in the company, valued at approximately $44,710.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other 4D Molecular Therapeutics news, insider Scott Bizily sold 1,750 shares of the firm’s stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $25.74, for a total value of $45,045.00. Following the completion of the transaction, the insider now owns 1,737 shares of the company’s stock, valued at approximately $44,710.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO David Kirn sold 92,001 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $27.13, for a total transaction of $2,495,987.13. Following the completion of the transaction, the chief executive officer now directly owns 1,059,153 shares of the company’s stock, valued at approximately $28,734,820.89. The disclosure for this sale can be found here. In the last quarter, insiders sold 143,942 shares of company stock worth $4,074,435. Insiders own 10.70% of the company’s stock.

Wall Street Analyst Weigh In

FDMT has been the subject of several research reports. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Friday, March 1st. Jefferies Financial Group increased their price target on shares of 4D Molecular Therapeutics from $30.00 to $58.00 and gave the company a “buy” rating in a research note on Monday, April 1st. The Goldman Sachs Group reissued a “buy” rating and issued a $81.00 price target on shares of 4D Molecular Therapeutics in a research note on Wednesday, February 7th. BMO Capital Markets dropped their price target on shares of 4D Molecular Therapeutics from $70.00 to $63.00 and set an “outperform” rating for the company in a research note on Monday, April 1st. Finally, Barclays initiated coverage on shares of 4D Molecular Therapeutics in a research note on Monday, April 15th. They issued an “overweight” rating for the company. Ten investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, 4D Molecular Therapeutics currently has a consensus rating of “Buy” and an average price target of $44.22.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.